DK3193880T3 - Hæmning af den transiente receptor-potential-A1-ionkanal - Google Patents

Hæmning af den transiente receptor-potential-A1-ionkanal Download PDF

Info

Publication number
DK3193880T3
DK3193880T3 DK15774806.2T DK15774806T DK3193880T3 DK 3193880 T3 DK3193880 T3 DK 3193880T3 DK 15774806 T DK15774806 T DK 15774806T DK 3193880 T3 DK3193880 T3 DK 3193880T3
Authority
DK
Denmark
Prior art keywords
inhibition
ion channel
transient receptor
receptor potential
transient
Prior art date
Application number
DK15774806.2T
Other languages
English (en)
Inventor
Bertand L Chenard
Xinyuan Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3193880T3 publication Critical patent/DK3193880T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
DK15774806.2T 2014-09-19 2015-09-18 Hæmning af den transiente receptor-potential-A1-ionkanal DK3193880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052678P 2014-09-19 2014-09-19
PCT/US2015/051063 WO2016044792A1 (en) 2014-09-19 2015-09-18 Inhibiting the transient receptor potential a1 ion channel

Publications (1)

Publication Number Publication Date
DK3193880T3 true DK3193880T3 (da) 2020-06-02

Family

ID=54249631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15774806.2T DK3193880T3 (da) 2014-09-19 2015-09-18 Hæmning af den transiente receptor-potential-A1-ionkanal

Country Status (18)

Country Link
US (2) US10221177B2 (da)
EP (1) EP3193880B1 (da)
JP (4) JP6571173B2 (da)
CN (1) CN106715430B (da)
AU (1) AU2015317332B2 (da)
CA (1) CA2961412C (da)
CY (1) CY1123059T1 (da)
DK (1) DK3193880T3 (da)
ES (1) ES2788395T3 (da)
HR (1) HRP20200601T1 (da)
HU (1) HUE049253T2 (da)
LT (1) LT3193880T (da)
PL (1) PL3193880T3 (da)
PT (1) PT3193880T (da)
RS (1) RS60192B1 (da)
SI (1) SI3193880T1 (da)
TW (1) TWI704149B (da)
WO (1) WO2016044792A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
HUE049253T2 (hu) * 2014-09-19 2020-09-28 Lilly Co Eli A tranziens receptor potenciál A1 ion csatorna gátlása
WO2016184313A1 (zh) 2015-05-20 2016-11-24 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
TWI690529B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
TWI690526B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
EP3299371B1 (en) 2015-05-20 2021-08-25 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and use thereof
WO2018109155A1 (en) * 2016-12-16 2018-06-21 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
WO2019152465A1 (en) 2018-01-31 2019-08-08 Eli Lilly And Company Inhibiting the transient receptor potential a1 ion channel
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
US12194046B2 (en) 2021-03-09 2025-01-14 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
KR102941181B1 (ko) 2021-08-20 2026-03-18 주식회사 엘지에너지솔루션 충방전 전력 제어 장치, 에너지 저장 시스템 및 에너지 저장 시스템의 동작 방법
US20250064846A1 (en) * 2022-01-07 2025-02-27 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
CN114671876B (zh) * 2022-04-27 2023-10-03 成都施贝康生物医药科技有限公司 新型茶碱类化合物、异构体或盐及其制备方法和用途
JP2023180673A (ja) * 2022-06-10 2023-12-21 日本メナード化粧品株式会社 Trpチャネル活性抑制剤
CN116655635B (zh) * 2023-05-19 2024-01-26 济南爱思医药科技有限公司 黑茶茶碱衍生物及在制备药物中的应用
US20250367323A1 (en) * 2024-05-31 2025-12-04 The Uab Research Foundation Platform for radiolytic neuromodulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
ES2609912T3 (es) * 2007-06-22 2017-04-25 Hydra Biosciences, Inc. Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1
WO2009140517A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US20120046305A1 (en) * 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
AR087501A1 (es) 2011-08-09 2014-03-26 Hydra Biosciences Inc Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位a1離子通道之抑制
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
HUE049253T2 (hu) * 2014-09-19 2020-09-28 Lilly Co Eli A tranziens receptor potenciál A1 ion csatorna gátlása

Also Published As

Publication number Publication date
JP2021120403A (ja) 2021-08-19
US20170275285A1 (en) 2017-09-28
ES2788395T3 (es) 2020-10-21
EP3193880A1 (en) 2017-07-26
US10519158B2 (en) 2019-12-31
JP2023015338A (ja) 2023-01-31
JP2017528490A (ja) 2017-09-28
JP2019206577A (ja) 2019-12-05
WO2016044792A1 (en) 2016-03-24
AU2015317332B2 (en) 2019-07-18
CA2961412A1 (en) 2016-03-24
CN106715430A (zh) 2017-05-24
AU2015317332A1 (en) 2017-03-16
SI3193880T1 (sl) 2020-06-30
LT3193880T (lt) 2020-05-11
US20190330212A1 (en) 2019-10-31
RS60192B1 (sr) 2020-06-30
TW201625619A (zh) 2016-07-16
CA2961412C (en) 2024-01-16
US10221177B2 (en) 2019-03-05
TWI704149B (zh) 2020-09-11
PL3193880T3 (pl) 2020-09-07
JP7181967B2 (ja) 2022-12-01
CY1123059T1 (el) 2021-10-29
CN106715430B (zh) 2019-09-17
PT3193880T (pt) 2020-06-19
HRP20200601T1 (hr) 2020-07-10
JP6571173B2 (ja) 2019-09-04
EP3193880B1 (en) 2020-03-25
HUE049253T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
DK3193880T3 (da) Hæmning af den transiente receptor-potential-A1-ionkanal
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3134410T3 (da) Hæmning af ionkanalen af overgangsreceptorpotentialet A1
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3370949T3 (da) Sammensætning af tætningsmiddel
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
EP3430073A4 (en) COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION
DK3418273T3 (da) Derivater af flavagliner
EP3394078A4 (en) INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
EP3398975A4 (en) LIGHT-SENSITIVE COMPOSITION
DK3363148T3 (da) Afdækning af krypteringsanvendelse
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254502A0 (en) Solid forms of menaquinols
DK3370515T3 (da) Anordning til påvisning af væggelus
EP3394079A4 (en) INHIBITORS OF GLUCOCORTICOIDREZEPTORS
DK3331498T3 (da) Nasalsammensætning